Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Erbitux · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Patients with metastatic EGFR-positive colorectal carcinoma |
| Name | Type | Description |
|---|---|---|
| Erbitux (Cetuximab) | BIOLOGICAL | 400 mg/m2 initial dose, 250 mg/m2 weekly |
Inclusion Criteria: * Provided signed written informed consent. * Histologically- or pathologically- confirmed metastatic colorectal carcinoma; * Documented progressive disease after receiving either: 1. at least two chemotherapy regimens for metastatic disease or 2. adjuvant therapy plus one ...
Erbitux is a monoclonal antibody being studied for the treatment of colorectal neoplasms, specifically in patients with metastatic colorectal carcinoma. It is currently in Phase 2 clinical development and is not yet approved for this indication.
Erbitux is a monoclonal antibody, but its specific molecular target is not disclosed in the available information. It is being investigated for its potential role in treating colorectal cancer, though the exact mechanism of action has not been detailed.
Erbitux is being developed by Eli Lilly and Company, a pharmaceutical company listed on the stock exchange under the ticker symbol LLY. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with colorectal cancer.
Erbitux is currently in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 trial has been completed, involving 250 patients with metastatic colorectal carcinoma.
Erbitux has one completed clinical trial, identified as NCT00044863, titled 'Study of Erbitux (Cetuximab) in Patients With Metastatic Colorectal Carcinoma.' This Phase 2 study enrolled 250 participants in the United States and was not randomized, double-blind, or controlled.
Erbitux is also known as Cetuximab, as indicated in the clinical trial title. The trial NCT00044863 refers to the drug as Erbitux (Cetuximab), confirming that these names refer to the same investigational agent.